[Cardiovascular events: a class effect by COX-2 inhibitors].
Araujo
Leila Fernandes
LF
Instituto do Coração, Hospital das Clínicas, FMUSP, São Paulo, SP.
Soeiro
Alexandre de Matos
Ade M
Fernandes
Juliano de Lara
Jde L
Serrano Júnior
Carlos Vicente
CV
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D006801:Humans; D007783:Lactones / Q000009:adverse effects; D011358:Product Surveillance, Postmarketing; D011720:Pyrazoles / Q000009:adverse effects; D018570:Risk Assessment; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones / Q000009:adverse effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib